KRAS and intrahepatic cholangiocarcinoma: MYC was also shown to facilitate the conversion of precancerous to cancerous cells in KRAS-G12D mutant fibroblasts and control the generation of self-renewing metastatic pancreatic cancer stem cells.177 In fact, in the context of KRAS-mutant PDAC, MYC promotes ductal-neuroendrocrine lineage plasticity, correlating with poorer survival and chemotherapy resistance.178 Additionally, it was recently described that in KRAS-driven primary liver cancer (PLC), MYC impacts lineage commitment to hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma (iCCA).